The ultimate goal of periodontal therapy has always been the regeneration of the lost periodontal supporting structures. Several methods have been employed over time to achieve this goal. Guided tissue regeneration (GTR) using bone grafts, barrier membranes or a combination of both has been the most commonly used approach. The results obtained from these treatments have been shown to be superior to open flap debridement (1) (2) (3) (4) . However, GTR has been proven to be very technique sensitive and the results achieved were often unpredictable (4) . This can be attributed by frequent exposure (4) of the implanted materials to the oral cavity and many other factors such as interproximal bone level, defect morphology, wound control, smoking habit and poor oral hygiene (5) (6) (7) (8) (9) (10) . Consequently, a search began for second-generation regenerative agents. Among these agents, EMDs have become the first bioactive agent to be used in periodontal clinical practice. The commercially available product is called Emdogain (Strauman international, Basel, Switzerland). EMD is obtained from developing teeth germs of 6-mo-old piglets (11) and is believed to participate in the development of periodontal supporting structures during tooth-formation processes (12) such as amelogenesis (13) . Furthermore, EMD can also exert effects on cell attachment, spreading, chemotaxis, proliferation and cell survival (14) . Moreover, EMD has the The clinical efficacy of EMDs for the treatment of periodontal infrabony defects has been reported. However, recent publications have questioned the validity of results from early findings. Hence, the purpose of this study was to compare the results obtained from early and late studies when EMD was used as an adjunct in treating human intrabony defects during flap surgery. The aim of this meta-analysis was to evaluate the validity of results published from early studies compared with those published from later studies.
Material and Methods:
PubMed and MEDLINE searches were performed. The evaluation period was 1997-2010 and it was divided into two groups of equal periods of time: early studies (1997) (1998) (1999) (2000) (2001) (2002) (2003) and late studies (2004) (2005) (2006) (2007) (2008) (2009) (2010) . The clinical parameters assessed were clinical attachment level (CAL), probing pocket depth and bone gain (BG; measured as a percentage or in mm).
Results: No statistically significant difference was found between the results obtained from early studies (1997) (1998) (1999) (2000) (2001) (2002) (2003) and late studies (2004-2010) with regards to CAL gain, probing pocket depth reduction and BG. Nonetheless, both study periods showed a benefit for using EMD to treat periodontal infrabony defects when compared with the groups without EMD during open flap surgery.
Conclusions:
The results obtained from this study failed to show any potential differences between the results published from early studies and late studies with regards to the clinical effectiveness of EMD in treating periodontal infrabony defects.
capacity to express growth factors, cytokines and extracellular matrix components, as well as molecules pertinent to osteogenesis and osteoclastogenesis (14) . Lastly, EMD possesses antibacterial function which is largely attributed to its vehicle, propylene glycol alginate (14, 15) . EMD has also been shown to enhance periodontal regeneration after surgery (11) , to improve treatment results in intrabony and mandibular Class II furcation defects (2), to minimize postsurgical complications when used as an alternative to GTR barrier membrane (16) and to aid soft tissue root-coverage procedures (17) .
Generally, studies published around the time that a product is launched often report favorable clinical outcomes (18) (19) (20) . However, a recent publication documented inferior results of EMD in noncontained defects when compared with GTR (21) . Hence, the aim of this meta-analysis was to determine any differences between the results of early studies and late studies results when EMD was used as an adjunct to treat human intrabony defects during flap surgery.
Material and methods
PubMed and MEDLINE searches were performed for the period January 1997 to July 2010. Articles included were clinical trials in which EMD was used for the treatment of intrabony defects. The search used the medical subject heading (MeSH) terms Emdogain, enamel matrix derivatives, enamel matrix proteins, dental enamel proteins, periodontal intrabony defects and biologic agents. Twenty early studies (carried out in the time-period from 1997 to 2003) met the inclusion criteria (18) (19) (20) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . A total of 11 studies reported BG after treatment with EMD: four reported BG in both mm and as a percentage (14, 18, 19, 24, 37) ; five studies reported BG in mm (22, 27, 28, 31, 36) ; and only two reported BG as a percentage (25, 26) . Eighteen late studies (carried out in the time-period 2004-2010) met the inclusion criteria (16, 21, 27, (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) . A total of nine studies evaluated BG: three reported BG in both mm and as a percentage (41) (42) (43) 53) ; five reported BG in mm only (44, 46, 50, 52, 53) ; and one study reported bone gain only as a percentage (48) (Tables 1A,B) .
The statistical analysis was performed by the Center for Statistical Consultation and Research at the University of Michigan. We used a random-effects meta-analysis to combine information from the 39 studies included in this meta-analysis, stratified by group (early studies vs. late studies). A random-effects metaregression was used to compare the effect of each outcome variable for early studies vs. late studies. All statistical analyses were carried out using STATA SE version 11.2/ (StataCorp LP, 4905 Lakeway Drive, College Station, TX 77845, USA). 
Clinical attachment level
In general, there was a significant overall increase in CAL [overall mean increase in attachment level = 3.048 mm, 95% confidence interval (95% CI) = 2.658-3.437; p < 0.001]. This effect was not significantly different for early studies vs. late studies (p = 0.526). The mean increase in CAL for the early studies group was 3.150 mm (95% CI = 2.585-3.715 mm; p < 0.001) whereas for the late studies group, the mean increase in CAL was 2.937 mm (95% CI = 2.423-3.450 mm; p < 0.001) (Fig. 1 ).
Probing pocket depth reduction
Similarly to the gains in CAL, there was a significant overall reduction of probing pocket depth; the overall mean reduction of probing pocket depth was 4.049 (95% CI = 3.659-4.440; p < 0.001). This effect was not significantly different between early studies and late studies (p = 0.231). The mean probing pocket depth reduction for early studies was 4.223 mm (95% CI = 3.606-4.841 mm; p < 0.001), whereas it was 3.845 mm (95% CI = 3.516-4.175 mm; p < 0.001) for late studies (Fig. 2 ).
Bone gain (%)
When BG was examined as a percentage, a statistically significant increase of 43.024% (95% CI = 30.486-55.563%; p < 0.001) was found. However, this was not statistically significantly different between early studies and late studies (p < 0.023). Mean BG was 36.212% (95% CI = 21.030-51.395%; p < 0.001) for the early studies and 59.292% (95% CI = 54.109-64.474%, p < 0.001) for the late studies. Nonetheless, these results should be regarded with great care because data were available from only two studies in the early studies group (Fig. 3) . (Fig. 4) .
Discussion
EMD has been a subject of extensive research, ranging from early investigations to prove its efficacy (18, 26, 30) to late investigations in combination with other regenerative therapy studies were used that were at low risk for bias. These findings are in contrast to the results reported on CAL gains in our investigation (3.09 mm) and might be explained by a more stringent exclusion of studies in EspositoÕs group. Another arm of the meta-analysis of Esposito et al. evaluated the clinical outcomes of EMD vs. GTR and reported no significant difference between the two groups. However, more postoperative complications and recession occurred in the GTR-treated sites. The authors acknowledged the difficulty of the attempted comparisons as a result of the great heterogeneity between the study designs and the outcomes reported (55, 56) .
Rathe et al. conducted a systematic review evaluating the efficacy of EMD for treating intrabony defects; they concluded that EMD can be used predictably for regeneration of intrabony defects, but found that EMD appears to be more effective in well-contained defects. Furthermore, the amount of bone regeneration was less than achieved with GTR (57). Generally our findings, as far as can be compared, also suggest a significant effectiveness of EMD in intrabony defects, but the amount of bone regeneration seems to be less pronounced. A comparison between GTR and EMD was not attempted in this meta-analysis and would be valuable for a future comparison. A benefit associated with the use of EMD can be found when minimally invasive surgical protocols are employed and in esthetic areas (45, 58, 59) . These benefits relate to the ease of application of EMDs. These parameters were not included in the present study design and would be of great interest in future investigations. Siciliano et al. (21) evaluated the performance of EMD vs. GTR in deep, noncontained defects and their results were in favor of the GTR therapy. Clinical application of the above-discussed findings indicates that EMD exhibits potential for regeneration in wellcontained periodontal defects, to enhance wound healing and as an adjunct to root coverage procedures combined with Coronnally Advanced Flap. This might be attributed to the effect of EMD in promoting early soft-tissue healing and subsequent enhancement of wound closure (17, 60, 61) .
In addition, data from this metaanalysis demonstrated a radiographic BG of 43.02% and 2.35 mm when EMD plus periodontal flap surgery was used for the treatment of intrabony defects. To the best of our knowledge, no other published metaanalysis has reported BG as a percentage or in mm. When these findings were compared with the available data from the Annals of Periodontology, the efficacy of EMD appeared uncertain (2,3) as a conventional periodontal flap procedure can achieve a mean BG of 40-50%, which is comparable with the results reported for EMD in this metaanalysis. One can assume that there was minimal added benefit of EMD as the percentage of BG was almost identical to that achieved using the conventional flap surgical procedure. Nonetheless, the benefits of biologic agents, such as EMD, cannot simply be disregarded. Postoperative complications after GTR, for example membrane exposure, have been reported to occur in almost 75% of sites; however, in the EMD group only 6% of subjects experienced similar adverse events (16) . Lastly, the effect of EMD on BG has been reported to be less marked than with conventional GTR (57).
To our knowledge, a comparison between early studies (1997) (1998) (1999) (2000) (2001) (2002) (2003) vs. late studies (2004) (2005) (2006) (2007) (2008) (2009) (2010) regarding the treatment of periodontal intrabony defects using EMD has not previously been attempted. Comparison of early studies with late studies identified no statistically significant difference in the efficacy of EMD determined using the following clinical parameters: CAL, probing pocket depth or BG (expressed either as a percentage or in mm).
The limitations of this present investigation are the limited sample size, the timelines selected (which could have been further divided into 
Conclusions
This meta-analysis failed to show any significant differences between the clinical results published in early or later studies regarding the use of EMD to treat periodontal intrabony defects.
